These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4625586)

  • 61. Cutaneous and parenteral studies with vehicles containing isopropyl myristate and peanut oil.
    Fitzgerald JE; Kurtz SM; Schardein JL; Kaump DH
    Toxicol Appl Pharmacol; 1968 Nov; 13(3):448-53. PubMed ID: 4973186
    [No Abstract]   [Full Text] [Related]  

  • 62. Primary packaging considerations in developing medicines for children: oral liquid and powder for constitution.
    Campbell GA; Vallejo E
    J Pharm Sci; 2015 Jan; 104(1):52-62. PubMed ID: 25393927
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmaceutical optimization of lipid-based dosage forms for the improvement of taste-masking, chemical stability and solubilizing capacity of phenobarbital.
    Monteagudo E; Langenheim M; Salerno C; Buontempo F; Bregni C; Carlucci A
    Drug Dev Ind Pharm; 2014 Jun; 40(6):783-92. PubMed ID: 23607724
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Aspects of tolerance to and dependence on cannabis.
    Wikler A
    Ann N Y Acad Sci; 1976; 282():126-47. PubMed ID: 828472
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Subacute toxicity of aqueous-suspended 9 -tetrahydrocannabinol in rats.
    Phillips RN; Brown DJ; Martz R; Hubbard JD; Forney RB
    Toxicol Appl Pharmacol; 1972 May; 22(1):45-9. PubMed ID: 5064307
    [No Abstract]   [Full Text] [Related]  

  • 67. Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.
    Chun AW; Freshwater RE; Taft DR; Gillum AM; Maniar M
    Biopharm Drug Dispos; 2011 Mar; 32(2):99-111. PubMed ID: 21341279
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Role of drug metabolism in drug research and development: importance of drug metabolism in clinical pharmacological evaluation of new drugs.
    Lemberger L
    J Pharm Sci; 1972 Oct; 61(10):1690-4. PubMed ID: 5072433
    [No Abstract]   [Full Text] [Related]  

  • 69. Oral vs parenteral drug effects on schedule-controlled behavior in rhesus monkeys.
    Downs DA; Miller LE; Wiley JN; Johnston DE
    Life Sci; 1980 Apr; 26(14):1163-8. PubMed ID: 6771480
    [No Abstract]   [Full Text] [Related]  

  • 70. Interactions in man of delta-9-tetrachydrocannabinol. 1. Alphamethylparatyrosine.
    Hollister LE
    Clin Pharmacol Ther; 1974 Jan; 15(1):18-21. PubMed ID: 4808739
    [No Abstract]   [Full Text] [Related]  

  • 71. Effects of the oral administration of Cannabis sativa (dagga) on chacma baboons (Papio ursinus).
    Ames FR; Brownell B; Zuurmond TJ
    S Afr Med J; 1979 Jun; 55(27):1127-32. PubMed ID: 113892
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Composition and preparation of fatty emulsions for parenteral feeding].
    Kachorovs'kyĭ BV; Zhoylo FA
    Farm Zh; 1970; 25(5):3-11. PubMed ID: 4994247
    [No Abstract]   [Full Text] [Related]  

  • 73. Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs.
    Wang JJ; Sung KC; Hu OY; Yeh CH; Fang JY
    J Control Release; 2006 Oct; 115(2):140-9. PubMed ID: 16959357
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intravenous injection in man of 9 -tetrahydrocannabinol and 11-OH- 9 -tetrahydrocannabinol.
    Perez-Reyes M; Timmons MC; Lipton MA; Davis KH; Wall ME
    Science; 1972 Aug; 177(4049):633-5. PubMed ID: 4558903
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration.
    Mahmoud DB; Shukr MH; Bendas ER
    Int J Pharm; 2014 Dec; 476(1-2):60-9. PubMed ID: 25269009
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Panel discussion: practical importance of generic equivalence.
    Ann Clin Res; 1974; 6(0):suppl 11:79-88. PubMed ID: 4212521
    [No Abstract]   [Full Text] [Related]  

  • 77. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Coenzyme Q10 stability in pediatric liquid oral dosage formulations.
    Estévez PN; Tripodi V; Buontempo F; Lucangioli S
    Farm Hosp; 2012; 36(6):492-7. PubMed ID: 23461442
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration.
    Hollister LE; Gillespie HK
    Clin Pharmacol Ther; 1973; 14(3):353-7. PubMed ID: 4698563
    [No Abstract]   [Full Text] [Related]  

  • 80. Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey.
    Ellison T
    Arch Int Pharmacodyn Ther; 1972 Feb; 195(2):213-30. PubMed ID: 4622666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.